Loading market dashboard
Rapid Micro Biosystems, Inc.
RPIDHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
LEXINGTON, Mass. , May 18, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. ("Rapid Micro Biosystems") (Nasdaq: RPID), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the pricing of its underwritten offering consisting of 3,581,000 shares of its Class A common stock and accompanying Series A warrants to purchase an aggregate of 3,581,000 shares of Class A common stock (or pre-funded warrants in lieu thereof) and Series B warrants to purchase an aggregate of 3,581,000 shares of Class A common stock (or pre-funded warrants in lieu thereof), and (ii) in lieu of common stock, to certain investors, pre-funded warrants, with an exercise price of $0.
Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to support the future success of the Company. Certain directors and officers of the Company are also investing in a concurrent registered offering Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to support the future success of the Company. Certain directors and officers of the Company are also investing in a concurrent registered offering
Rapid Micro Biosystems NASDAQ: RPID reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook, citing momentum in system placements, consumables and recurring revenue, while management said gross margin improvement remains a central priority for the year.
Rapid Micro Biosystems, Inc. (RPID) Q1 2026 Earnings Call Transcript
Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.26 per share a year ago.
LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2026.
LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2026 financial results after the market close on Wednesday, May 13, 2026.
Rapid Micro Biosystems (RPID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rapid Micro Biosystems (NASDAQ: RPID) reported fourth-quarter and full-year 2025 results highlighting record quarterly revenue, increased system placements, and expanding recurring revenue, while also outlining expectations for revenue growth and gross margin improvement in 2026. Fourth-quarter results set revenue and placement records Management said fourth-quarter revenue rose 37% year-over-year to a quarterly record of $11.3 million,
Rapid Micro Biosystems, Inc. posted strong FY25 revenue growth, driven by Growth Direct system placements, but remains unprofitable with a $47M net loss. RPID's growth hinges on large multi-system orders from major pharmaceutical manufacturers, with recurring revenue from consumables and services now 53% of total revenue. A premium valuation (6.4x P/S) reflects high expectations for platform adoption, but negative margins and ongoing cash burn temper near-term optimism.
Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript
Reports record fourth quarter 2025 total revenue of $11.3 million , representing 37% growth compared to fourth quarter 2024 Reports full year 2025 total revenue of $33.6 million , representing 20% growth compared to 2024 Amgen expands global Growth Direct system rollout with significant multi-system order in the fourth quarter 2025; will sponsor North American Growth Direct Day in the second quarter 2026 Samsung Biologics continues to expand Growth Direct deployment across its manufacturing network with a meaningful multi-system order in the first quarter 2026 For the full year 2026, the Company expects total revenue in the range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements and gross margin percentage of approximately 20% LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Companies deepen partnership to advance automated, integrated microbiology quality control Companies deepen partnership to advance automated, integrated microbiology quality control
LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the KeyBanc Capital Markets Healthcare Forum.
